ImmunityBio director sells 25K shares in plan trade

ImmunityBio, Inc. director Barry J. Simon reported an open-market sale of common stock.

Rhea-AI Filing Summary

ImmunityBio, Inc. director Barry J. Simon reported an open-market sale of common stock. On June 24, 2026, he sold 25,000 shares at a weighted average price of $7.8763 per share, in a trade executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 18, 2025. After this transaction, he continues to hold 2,802,788 shares of ImmunityBio common stock directly.

Insider Trade Summary 10b5-1

Net Seller: 25,000 shares

Net Sell 1 txn

Insider Simon Barry J.

Role Director

Sold 25,000 shs ($197K)

Type	Security	Shares	Price	Value
Sale	Common Stock	25,000	$7.8763	$197K

Holdings After Transaction: Common Stock — 2,802,788 shares (Direct)

Footnotes (2)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025.
2. F2. Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $7.875 to $7.885 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 25,000 shares Weighted average sale price: $7.8763 per share Shares held after transaction: 2,802,788 shares +2 more

5 metrics

Shares sold 25,000 shares Open-market sale of ImmunityBio common stock on June 24, 2026

Weighted average sale price $7.8763 per share Aggregate price for 25,000 shares sold within $7.875–$7.885 range

Shares held after transaction 2,802,788 shares Direct ownership of ImmunityBio common stock following the sale

Rule 10b5-1 plan adoption date December 18, 2025 Pre-arranged trading plan governing the reported sales

Net share direction 25,000-share net sale transactionSummary shows net-sell of 25,000 shares

Key Terms

Rule 10b5-1 trading plan, open-market sale, weighted average share price, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: "open-market sale" for 25,000 shares of Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average share price financial

"Represents the weighted average share price of an aggregate total of 25,000 shares sold..."

The weighted average share price is the average price of a stock calculated by giving each recorded trade price a weight proportional to the number of shares traded at that price (or, more generally, by the relevant share quantity for each price). It is computed as the sum of (price × shares) for all transactions divided by the total shares traded, so prices with larger volumes have a bigger effect than low-volume prices; this contrasts with a simple (unweighted) average that treats every price equally.

Form 4 regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan..."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ImmunityBio (IBRX) director Barry J. Simon report?

Barry J. Simon reported an open-market sale of 25,000 shares of ImmunityBio common stock. The transaction occurred on June 24, 2026 at a weighted average price of $7.8763 per share, according to the Form 4 filing.

At what price did ImmunityBio (IBRX) shares sell in Barry J. Simon’s Form 4?

The 25,000 ImmunityBio shares were sold at a weighted average price of $7.8763. Footnotes state the trades occurred within a price range from $7.875 to $7.885 per share, reflecting multiple executions during the sale.

How many ImmunityBio (IBRX) shares does Barry J. Simon hold after this sale?

Following the reported sale, Barry J. Simon directly holds 2,802,788 shares of ImmunityBio common stock. This post-transaction ownership figure comes from the Form 4 and shows his remaining direct equity position after the 25,000-share disposition.

Was the ImmunityBio (IBRX) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Barry J. Simon on December 18, 2025. Such plans pre-arrange trades, reducing the significance of short-term timing.

What does the price range disclosure mean in the ImmunityBio (IBRX) Form 4?

The filing explains the 25,000 shares were sold between $7.875 and $7.885 per share. The reported $7.8763 is a weighted average, and the reporting person offers to provide full breakdowns by individual execution price upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2026 - 09:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simon Barry J.

(Last) (First) (Middle)

C/O IMMUNITYBIO, INC.

3530 JOHN HOPKINS COURT

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/24/2026		S(1)		25,000	D	$7.8763(2)	2,802,788	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025.

2. Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $7.875 to $7.885 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Remarks:

	/s/ David C. Sachs, as Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)